Northwest Wealth Management LLC raised its stake in shares of NewLink Genetics Corporation (NASDAQ:NLNK) by 3.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 58,022 shares of the biotechnology company’s stock after buying an additional 1,740 shares during the period. Northwest Wealth Management LLC’s holdings in NewLink Genetics Corporation were worth $426,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Teza Capital Management LLC acquired a new position in shares of NewLink Genetics Corporation during the first quarter valued at about $312,000. UBS Asset Management Americas Inc. acquired a new position in shares of NewLink Genetics Corporation during the first quarter valued at about $297,000. Bank of New York Mellon Corp boosted its position in shares of NewLink Genetics Corporation by 59.6% in the first quarter. Bank of New York Mellon Corp now owns 202,540 shares of the biotechnology company’s stock valued at $4,881,000 after buying an additional 75,610 shares during the period. First Trust Advisors LP acquired a new position in shares of NewLink Genetics Corporation during the first quarter valued at about $620,000. Finally, C WorldWide Group Holding A S acquired a new position in shares of NewLink Genetics Corporation during the first quarter valued at about $261,000. Hedge funds and other institutional investors own 51.41% of the company’s stock.
NewLink Genetics Corporation (NASDAQ NLNK) traded up 0.96% during midday trading on Tuesday, hitting $7.39. 103,812 shares of the stock were exchanged. The stock’s market cap is $215.97 million. The company’s 50 day moving average is $7.42 and its 200-day moving average is $14.09. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17.
NewLink Genetics Corporation (NASDAQ:NLNK) last issued its earnings results on Thursday, May 4th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.10. NewLink Genetics Corporation had a negative net margin of 250.91% and a negative return on equity of 61.98%. The company had revenue of $2.76 million for the quarter, compared to the consensus estimate of $2.68 million. On average, analysts expect that NewLink Genetics Corporation will post ($3.05) earnings per share for the current year.
WARNING: This story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/07/25/northwest-wealth-management-llc-acquires-1740-shares-of-newlink-genetics-corporation-nlnk.html.
Several brokerages have issued reports on NLNK. Zacks Investment Research cut shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, April 4th. SunTrust Banks, Inc. upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and upped their price target for the company from $12.00 to $30.00 in a research report on Thursday, March 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $32.00 price target (up from $20.00) on shares of NewLink Genetics Corporation in a research report on Saturday, April 22nd. Stifel Nicolaus restated a “buy” rating and issued a $26.00 price target on shares of NewLink Genetics Corporation in a research report on Saturday, April 22nd. Finally, Jefferies Group LLC upped their price objective on shares of NewLink Genetics Corporation from $15.00 to $18.00 and gave the company a “hold” rating in a research note on Thursday, April 6th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. NewLink Genetics Corporation presently has an average rating of “Hold” and a consensus price target of $19.17.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corporation (NASDAQ:NLNK).
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
